Celonic launches stand-alone GMP analytics portfolio
Challenging positions in upstream processing
At Celonic, our vision is to serve our customers according to the actual market needs. Following this strategy, Celonic has already collected a full range of experiences with actual biosimilars. This comprises the development of highly scale-up stable and regulatory compliant GMP cell lines producing at high titre under serum free, chemically defined conditions, the development of efficient USP and DSP, later with excellent yields from harvest as well as the development of analytical methods to show and approve comparability.
Do you want to know more? Please contact us!
Key words: biosimilars, biobetter, Herceptin, Trastuzumab, Avastin, Bevacizumab, Erbitux, Cetuximab, MabThera, Remicade, Infliximab, Enbrel, Rituxan, Rituximab, Humira, Adalimumab, Lantus, Neulasta, Epogen, NovoRapid, Procrit, Aranesp, Xolair, Omalizumab, Campath, Alemtuzumab, Vectibix, Panitumumab, Synagis, Palivizumab, Prolia, Denosumab, hFSH, hGH, human growth hormone, human follicle stimulating hormone, fusion proteins, coagulation factors, Fusionsprotein, Wachstumshormon, Folikelstimmulierender Faktor, Koagulationsfaktoren